孟鲁司特钠治疗儿童咳嗽变异性哮喘临床疗效观察

目的观察白三烯受体拮抗剂孟鲁司特钠治疗儿童咳嗽变异性哮喘(CVA)的临床疗效,为CVA治疗提供参考。方法将134例CVA患儿根据有无选用孟鲁司特钠治疗分为治疗组71例和对照组63例。对照组仅予以常规治疗,治疗组在对照组治疗基础上加服孟鲁司特钠治疗。记录2组患儿的咳嗽缓解时间及咳嗽消失时间,随访2个月观察有无复发。结果 2组咳嗽明显好转时间比较差异无统计学意义(P>0.05)。但治疗组咳嗽消失时间短于对照组;复发率为2.8%(2/71),低于对照组的12.7%(8/63),差异均有统计学意义(P<0.05)。结论在CVA患儿治疗中,孟鲁司特钠在咳嗽症状消失及复发方面具有明确疗效,不失为一种理想的用药选择,值得临床推广应用。

The clinical efficacy of singulair in treatment of children with cough variant asthma

Objective To evaluate the effect of leukotriene receptor antagonist montelukast in treatment of children with cough variant asthma （CVA） and provide reference for the treatment of CVA . Methods 134 cases of CVA children in the Pediatric Department were enrolled according to whether take montelukast treatment, they were divided into the treatment group of 71 cases and the control group of 63 cases. The control group only received conventional therapy,while the treatment group was added with montelukast for treatment based on the control group. The cough relief time, cough disappeared time and the cough recurrence in 2 months follow-up in both groups were recorded. Results This study showed that the therapeutic ef- ficacy of the treatment group was significantly better than that in control group. Although the cough relieving time had no signif- icant difference in both groups （ P 〉 0.05）, the cough disappear time of the treatment group was shorter than that of the control group,the cough recurrence 2.8% （2/71） in 2 months follow-up（P =0.034） in treatment group were significantly lower than 12.7% （8/63）in the control group, and the differences were statistically significant （P 〈 0.05）. Conclusion The application of Singulai can alleviate cough symptom and the recurrence in CVA,which is an ideal drug selection for CVA and worth of clin- ical application.